Status:

COMPLETED

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis

Lead Sponsor:

Daiichi Sankyo Co., Ltd.

Conditions:

Osteoporosis

Eligibility:

All Genders

50+ years

Phase:

PHASE3

Brief Summary

Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)

Eligibility Criteria

Inclusion

  • Involutional (postmenopausal and senile) osteoporosis with prevalent fragility vertebral fractures

Exclusion

  • Any underlying condition,(other than BMD) that might have resulted in abnormal bone metabolism

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2012

Estimated Enrollment :

1262 Patients enrolled

Trial Details

Trial ID

NCT00680953

Start Date

May 1 2008

End Date

July 1 2012

Last Update

March 12 2015

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Fukuoka, Japan

2

Osaka, Japan

3

Sapporo, Japan

4

Tokyo, Japan